Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Travere Therapeutics Inc Common Stock (TVTX).
- Disclosed ownership: 7.8%.
- Date of event: 31 Dec 2024.
VANGUARD GROUP INC - 31 Dec 2024 SCHEDULE 13G/A Report for Travere Therapeutics Inc Common Stock (TVTX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- TVTX
- Shares outstanding
- 86,995,677 shares
- Disclosed Ownership
- 6,742,165 shares
- Ownership
- 7.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 31 Jan 2025, 10:09:31 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 30 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 7.8% ownership in Travere Therapeutics Inc Common Stock (TVTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Jan 2025, 10:09.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 7.8% | 6,742,165 | 0 | 53,801 | Ashley Grim | Head of Global Fund Administration |